Table 3. Changes in nude mouse body weight after treatment of mice with icotinib, docetaxel, or their combinations (n = 8 mice/group, mean ± SD).

Group	Initial body weight (g)	Ending body weight (g)	P value
Group A
Control	20.06 ± 0.37	24.25 ± 0.51
IcoR	20.28 ± 0.48	23.55 ± 0.24	< 0.05#,##
IcoH	20.19 ± 0.42	23.55 ± 0.32	< 0.05#,##
DTX	20.14 ± 0.34	23.08 ± 0.27	< 0.05#
Group B
IcoR+DTX	19.98 ± 0.45	23.00 ± 0.40	< 0.05#
IcoR-DTX	20.25 ± 0.43	23.03 ± 0.27	< 0.05#
DTX-IcoR	20.06 ± 0.39	22.93 ± 0.32	< 0.05#
Group C
IcoH+DTX	20.01 ± 0.35	22.91 ± 0.35	< 0.05#
IcoH-DTX	20.11 ± 0.43	23.00 ± 0.33	< 0.05#
DTX-IcoH	20.08 ± 0.39	23.09 ± 0.37	< 0.05#

Abbreviations: Control, negative control; DTX, docetaxel; IcoR, a regular icotinib dose; IcoH, a high icotinib dose; IcoH-D, a high icotinib dose and sequential docetaxel for 3-weeks of treatment; IcoR-D, a regular icotinib dose and sequential docetaxel for 3-weeks; IcoH+D, a high icotinib dose plus docetaxel for 3 weeks; IcoR+D, a regular icotinib dose plus docetaxel for 3 weeks; D-IcoR, docetaxel and sequential regular icotinib dose for 3 weeks; D-IcoH, docetaxel and sequential high icotinib dose for 3 weeks; TGIR, tumor growth inhibition rate.

^#P < 0.05 compared to the negative control; ^##P < 0.05 compared to docetaxel.